Zasocitinib Surpassed Deucravacitinib in Psoriasis Study
A new phase 3 clinical study found zasocitinib yielded higher skin clearance rates for adults with plaque psoriasis.
Updated on Oct. 13, 2026 in Arthritis
Live Poll
Would you trust a new medication more than an existing one if clinical trials showed higher effectiveness?
The LATITUDE Atlas phase 3 study of 604 participants revealed that zasocitinib outperformed deucravacitinib in achieving complete skin clearance at week 16. Researchers observed significantly higher PASI 90 and PGA 0 scores among those treated with 30 mg of zasocitinib daily compared to 6 mg of deucravacitinib.
Why it matters
The findings suggest that zasocitinib could become a potent new oral treatment option for adults managing moderate to severe plaque psoriasis. The study confirmed consistent efficacy metrics without identifying new safety signals during the 16-week treatment period.
The LATITUDE Atlas study of 604 participants showed 62.5% of zasocitinib recipients achieved PASI 90 compared to 34% for deucravacitinib. Researchers also noted 43% of the zasocitinib group reached PGA 0, versus 18.5% for the deucravacitinib group.
The players
Henry Ford Health
This is a prominent academic medical center that employed the principal investigator for the clinical study.
The details
The study assigned participants to receive either 30 mg of zasocitinib or 6 mg of deucravacitinib once daily over 16 weeks. Reported adverse events were consistent with previous findings and included nasopharyngitis, acne, and upper respiratory infections.
Timeline
The primary endpoints for skin clearance were assessed at week 16.
The Big Picture
The LATITUDE Atlas phase 3 study marks a significant step forward in the evolution of oral therapies for chronic inflammatory skin conditions. By demonstrating superior efficacy against an established comparator, this discovery shifts the current paradigm for treating moderate to severe plaque psoriasis.
The data suggests that patients with moderate to severe plaque psoriasis may soon have a more effective oral medication available to achieve clear skin. Patients should discuss these clinical trial results with their dermatologists to determine if emerging treatments might eventually suit their specific needs.
The takeaway
This study demonstrates that pharmacological advancements continue to improve outcomes for chronic dermatological conditions. Patients are encouraged to keep track of regulatory announcements regarding the availability of new, more effective oral therapies.
Further reading
Learn more about the latest research and standard care for autoimmune conditions in the Arthritis section.
Live Poll
Would you trust a new medication more than an existing one if clinical trials showed higher effectiveness?
